Kornimate/medical-research-clean huggingface dataset:
cardiovascular risk comparison between expanded hemodialysis using theranova and on-line hemodiafiltration

Conditions: Kidney Failure, Chronic; Renal Dialysis

Summary: theranova is a novel medium cut-off (mco) dialyzer. previous studies identified that theranova dialyzer had superior performance on middle molecule removal to conventional hemodialysis (hd) and hemodiafiltration (hdf). the present study addresses to compare clinical outcomes including cardiovascular endpoint between hd with theranova dialyzer and hdf.

while conventional hemodialysis (hd) modality effectively removes small-sized molecules, performance with middle-sized and protein-bound molecules is not well established. with increasing perception on importance of middle molecule removal, on-line hemodiafiltration (hdf) is getting more attention from healthcare professionals. however, hdf has not been widely used in korea due to its technical burden and limited public funding issue. novel medium cut-off (mco) dialyzer, theranova, is available in korea, which showed superior performance on middle molecule removal to conventional hd and hdf from the previous study. this new dialyzer can be a good alternative option replacing conventional hd or even hdf with its benefits. however, current data available on the mcp dialyzer has certain limitations such as small sample size, no asian subject included, limited types of biomarkers, and no clinical outcomes (particularly cardiovascular diseases) included. with this respect, performance comparison of mco dialyzer with hdf in terms of clinical outcomes, including cardiovascular endpoint would fill the exiting data gap, which is absolutely important to make a clinical decision on dialysis modality.

Eligibility criteria:
inclusion criteria: * 18 years old and older * hemodialysis more than 3 months because of end-stage renal disease * consent to the study protocol exclusion criteria: * already receiving online hemodiafiltration before study enrollment * dialysis schedule other than three times per week (e.g., once per week) * receiving concurrent peritoneal dialysis * having a plan to receive kidney transplantation within 1 year * having multiple myeloma or monoclonal gammopathy * having advanced or active malignancy * having a plan to be pregnant or being pregnant / breast-feeding or not having a plan to use contraception * participating in other clinical trials

Keywords: end-stage renal disease medium cut-off dialyzer hemodiafiltration cardiovascular pulse wave velocity
family inheritance, gene-gene and gene-environment interactions in the field of cardiovascular and renal diseases. fifth visit of the stanislas cohort

Conditions: Cardiovascular Diseases; Cohort Studies; Genotype; Risk Factors; Nutrition

Summary: the stanislas cohort is a monocentric familial longitudinal cohort originally comprised of 1006 families consisting of two parents and at least two biological children and deemed healthy, recruited in 1993-1995 at the centre for preventive medicine of nancy. this cohort was established with the primary objective of investigating gene-gene and gene-environment interactions in the field of cardiovascular diseases. the 5th visit of the stanislas cohort will allow a better evaluation of the cardiovascular ageing of the population and the transition toward cardiovascular or renal diseases in relation with their genetic profile and environment.

the main objective of the stanislas cohort is to identify the factors associated with cardiovascular aging (assessed through the study of the degradation of morphological and functional parameters of the heart and vascular systems). data (clinical, biological, morphological, genetic and lifestyle) from previous visits (the first having been initiated in the mid-1990s) will be considered as exposure and / or adjustment variables. the exposure variables of interest will be: * the components of metabolic syndrome (ms), * genetic determinants, through an approach of family segregation and candidate genes, * multi-omic biomarkers analyzed from the biological collection of the first assessments of the cohort * food intake, nutrition and eating behavior the secondary objectives are * identify the factors associated with a degradation of renal parameters (renal function and proteinuria). * identify the factors associated with a degradation of metabolic parameters. * to assess the association between sars-cov-2 infection (questionnaire and serological approach) and cardiovascular and renal parameters * identify factors associated with the occurrence of clinical cardiovascular events. * association between covid 19 events and general disabling symptoms * complete the cohort's biological collection for future biomarker assays related to previous objectives

Eligibility criteria:
inclusion criteria: * aged over 18 * person who participated in the stanislas cohort * person affiliated to a social security scheme or beneficiary of such a scheme * person having received complete information on the organization of the research and having signed an informed consent exclusion criteria: * persons deprived of their liberty by a judicial or administrative decision, persons undergoing psychiatric treatment under articles l. 3212-1 and l. 3213-1 * person referred to in articles l. 1121-5, l. 1121-7 and l1121-8 of the public health code: * pregnant woman, parturient or nursing mother * adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice) * person of full age unable to express consent
trimebutine on the development of adverse events related to the helicobacter pylori eradication medications

Conditions: Helicobacter Pylori Infection

Summary: adverse events related to the eradication medication is one of the reason of lower eradication success in the h. pylori treatment. the aim of this study was to evaluate the additive effect of trimebutine for the development of adverse events related to the h. pylori eradication regimen.

adverse events related to the eradication medication is one of the reason of lower eradication success in the h. pylori treatment. the common adverse events related to the eradication medications area as follows; abdomen discomfort, pain, nausea, vomiting, diarrhea, bloating, urticaria, dizziness, headache, etc,. various methods have been tried to reduce or prevent the adverse events related to the eradication medications. however, there is no established methods to reduce or prevent these events. the aim of this study was to evaluate the additive effect of trimebutine for the development of adverse events related to the h. pylori eradication regimen.

Eligibility criteria:
inclusion criteria: * subjects who underwent upper gastrointestinal endoscopy and were proven to have h. pylori infection either by using the rapid urease test, the 13 c-urea breath test (ubt), or histological examination. exclusion criteria: * subjects who took medications as proton pump inhibitor, histamin-2 receptor antagonist and antibiotics, * subjects who underwent stomach resection * subjects less than 18 years of age
preventing infections in orthopaedic patients

Conditions: Open Fracture

Summary: determine if antibiotic prophylaxis with intravenous cephalosporin and aminoglycoside in patients with type ii and ii open fractures is safe and effective.

1. determine the safety and efficacy of antibiotic prophylaxis in type ii and ii open fractures when using iv cephalosporin and aminoglycoside. 2. identify the incidence of acute kidney injury. 3. identify the type and number of associated infections 4. identify the antibiotic resistance profile noted 5. identify any secondary infections at sites other than the fracture site

Eligibility criteria:
inclusion criteria: * male or female \>= 18 years old * patients are diagnosed with a type ii or iii open fracture exclusion criteria: * prior to treatment, report of an allergy to beta-lactam or aminoglycoside antibiotics * pregnancy * did not receive 72 hours of iv antibiotic prophylaxis with 1st or 2nd generation cephalosporin and either gentamicin or tobramycin * receiving ongoing inpatient care
pulse contour analysis and tissue oxymetry in changing vascular tone

Conditions: Cardiac Output, High; Cardiac Output, Low; Vasodilation; Vasoconstriction; Hemodynamics

Summary: the purpose of this study is to compare changes of minimally invasive arterial pulse contour cardiac output with changes of intermittent and continuous thermodilution cardiac output by pulmonary artery catheter in hemodynamic unstable patients with rapid changing vascular tone (changing dosage of vasoactive drugs or inotropics, or volume challenge). simultaneously, global parameters of oxygen delivery and consumption will be compared with regional flow parameters and tissue oxymetry (near infrared spectrometry and laser-doppler). while continuous thermodilution cardiac output is used for patient management, pulse contour cardiac output, intermittent thermodilution cardiac output and tissue oxymetry is only used for monitoring.


Eligibility criteria:
inclusion criteria: * indication for invasive hemodynamic monitoring with pulmonary artery catheter and arterial catheter * hemodynamic instability (need for vasoactive drugs, inotropics or volume). exclusion criteria: * age \< 18. * patient with contraindications for the placement of arterial cannula. * patient with history or clinical findings of aortic valve regurgitation. * atrial fibrillation. * patient being treated with an intra-aortic balloon pump. * limitation of therapy due to bad prognosis

Keywords: arterial pulse contour cardiac output changing vascular tone tissue oxymetry prediction of fluid responsiveness
a study of t2000 in essential tremor

Conditions: Essential Tremor

Summary: this study will evaluate the safety and efficacy of t2000 when used to treat patients with moderate to severe essential tremor over a 20 week period. essential tremor (et) is a common form of involuntary shaking not related to parkinson's disease. the medications that are currently used to treat et work in a small proportion of patients and provide only partial improvement in symptoms. use of these current medications is also limited by side-effects in many patients. t2000 is a medication currently under development for the treatment of essential tremor. although t2000 is a new medication, it belongs to a class of medications that has been used for many years for the treatment of a variety of medical conditions. in previous studies, t2000 appeared to be effective in controlling symptoms of et and some patients with severe et had major improvements in tremor. t2000 was well tolerated for periods up to 20 days and the minimal side-effects seen were those that would be expected for medications in this class. the current study will evaluate the safety and efficacy of t2000 in patients with moderate to severe essential tremor. patients will receive doses of t2000 beginning at 600 mg a day, followed by 800 mg a day and up to 1000 mg a day. the total duration of treatment will be 20 weeks. patient's tremor and neurological examination will be monitored throughout the study. the response to t2000 will be determined by comparing the severity of tremor while patients are receiving t2000 compared to the tremor observed without active medication.


Eligibility criteria:
inclusion criteria: * confirmed essential tremor by nih criteria * significant functional activity limitation due to et * patients who have failed, are inadequately treated or cannot tolerate alternative treatments for et as well as treatment naïve patients who have considered but declined alternative treatment exclusion criteria: * patients adequately controlled without side effects on a current et treatment * pregnant patients or patients who may become pregnant during the study * patients with other medical conditions that may cause tremor, such as parkinson's disease or active hyperthyroidism * patients taking medications that might produce tremor or interfere with the evaluation of tremor such as cns-stimulants or beta-blockers * patients who must take medications that alter liver metabolism as well as patients with liver disease or coagulation disorders * patients with seizure disorders * patients with a history of allergy or hypersensitivity reaction to barbiturates or other related medications, such as phenobarbital or phenytoin * patient with significant general medical or clinical laboratory abnormalities

Keywords: movement disorder
utility of a survey instrument to predict benefit from a novel treatment for vertical heterophoria

Conditions: Binocular Vision Dysfunction; Vertical Heterophoria

Summary: patients with acute exacerbation of chronic headache disorder present frequently to the emergency department (ed) for pain management. a novel etiology of headaches is vertical heterophoria (vh), a poorly understood and little recognized binocular vision malady that when treated with realigning prismatic spectacle lenses results in marked reduction in headache and other associated vh symptoms. this study aims to determine the accuracy of the vertical heterophoria symptom questionnaire (vhsq) in identifying a ed headache patients who will experience significant reduction in vh symptoms with use of realigning prismatic spectacle lenses. this study's secondary purpose is to determine if vh is a common cause of chronic headache disorders in ed headache patients. to achieve these goals, a prospective observational study will be performed on ed headache patients \> 18 years old. all will be given the vhsq, and all will be assessed for a diagnosis of vh by an optometrist who will utilize a novel vh testing method. high and low score groups on the vhsq will then be compared to each other to determine the prevalence of vh in each.


Eligibility criteria:
initially include all patients presenting to emergency department with chief complaints of headache, head pain, face pain and/or migraine. inclusion criteria: * greater than or equal to 18 years old * ability to speak and read english * chronic headache disorder as defined by physician diagnosis, or greater than three months of headaches requiring symptom relief with medication more than once every two weeks, or having headaches so severe that previous emergency department evaluation or treatment was necessary exclusion criteria: * symptoms directly caused by trauma within the last three months * known tmj disorder and presenting with tmj pain * suspected infectious sinusitis or meningitis * pain originating from ear * pain originating from dental source * patient not willing or able to travel to study optometrist for follow-up * known history of cerebral aneurysm * known history of brain tumor * without previous ct, mri, or other imaging to assess patient's headache disorder * patient a prisoner * patient under temporary or permanent custodianship * patient currently with questionable state of mental competence * treating physician or study investigator believes patient to be inappropriate for study participation

Keywords: anxiety binocular chronic headache dizziness vertical heterophoria vision dysfunction
factors associated with recurrent falls in stroke patients

Conditions: Fall; Stroke

Summary: the goal of this observational study is to learn about the recurrent falls in patients with acute stroke. the main question\[s\] it aims to answer are: * what is the frequency of recurrent falls * which factors are associated with recurrent falls in patients with acute stroke. participants will be evaluated in terms of * frequency of recurrent falls within the six months after stroke * fear of falling * the stroke severity (canadian neurological scale), * ambulation level (functional ambulation classification), * functional disability (functional independence scale) * postural control and balance * functional status (modified rankin scale)

falling is common in stroke patients both in the hospital and at home after discharge. as a result, physical problems such as fractures and psychological problems such as fear of falling, limitation of physical activity and social isolation occur. identifying the factors that cause falls after stroke will contribute to the recovery process by preventing complications by taking the necessary precautions and increasing the patient's participation in rehabilitation. this study was planned to determine the frequency of falls in patients with acute stroke and to determine the risk factors associated with recurrent falls within the first six months after stroke.

Eligibility criteria:
inclusion criteria: 1. having an acute stroke over the age of 18 2. to have a cognitive situation to understand and answer questions exclusion criteria: 1. patients with bilateral hemiplegia 2. patients without motor involvement 3. those with a history of stroke 4. patients with severe cognitive impairment 5. patients in need of intensive care
effect of mandala coloring of circumcised children

Conditions: Circumcision

Summary: the aim of this study was to determine the effect of mandala painting on fear, anxiety, emotional symptoms and postoperative pain of circumcised children.

78 volunteer children between the ages of 6-12 who come for circumcision surgery will be randomly divided into two groups: mandala painting group and control group. children will be evaluated before, during and after the procedure. pain related to the circumcision procedure will be assessed using flacc pain scale, fear will be assessed using high fear scale, anxiety will be assessed using child anxiety-state scale and emotional state will be assessed using emotional indicators scale. in addition, children\&#39;s demographic data will be recorded in the information form.

Eligibility criteria:
inclusion criteria: children between the ages of 6-12, written and verbal consent given by their legal guardians, can speak and are literate in turkish, have sufficient mental development to answer questions exclusion criteria: children with congenital urological anomalies, children with who did not agree to participate in the study and who were not in the specified age group

Keywords: anxiety child circumcision emotional manifest fear pain mandala painting
tactile and kinaesthetic stimulation in neonates with hyperbilirubinaemia

Conditions: Neonatal Hyperbilirubinemia

Summary: hyperbilirubinemia is the most common problem seen in neonates, owing to severe complications in their lifetime. the study design of the study is pretest - a posttest experimental design. criterion-based purposive sampling will be used for recruiting the neonates. in the study neonates will be selected according to the selection criteria and will be allocated into two groups using computer-based randomization.the intervention group - neonates will receive tactile and kinesthetic stimulation for 15 minutes for 3 consecutive days, 1 hour after feeding twice daily along with phototherapy, control group - phototherapy alone will be given along with conventional nicu care. total serum bilirubin will be assessed as outcome measures daily once. transcutaneous bilirubin will be assessed after every intervention.


Eligibility criteria:
1. new born in neonatal intensive care unit 2. stable vitals 3. full term and preterm neonates 4. gestational age 34 weeks to 40 weeks 5. birth weight -1800 - 3000 g 6. apgar score at birth of 8 -10 7. total serum bilirubin levels \> 10 mg/dl
hematopoietic stem cell transplantation in myeloma

Conditions: Multiple Myeloma

Summary: the treatment assignment is based on the presence or absence of an hla-identical sibling donor (genetic randomisation, not formal randomisation). patients with suitable hla-identical sibling donors are offered a tandem transplant approach consisting of standard autografting nonmyeloablative radiotherapy and allografting. patients without hla-identical siblings are treated with standard double autologous transplantation as per institutional guidelines or enrolled in other treatment programs approved by local irbs.this is a multi-center study. the division of hematology of university of torino at the s.g.b. hospital, torino, italy, is the co-ordinating center.


Eligibility criteria:
inclusion criteria: * durie-salmon stage iia-iiib multiple myeloma; * age \> 18 and ≤ 65 years; * previously untreated myeloma; * presence of a sibling (potential donor); * bilirubins \< twice normal;alat and asat \< four times normal; * left ventricular ejection fraction \> 40%; * creatinine clearances \> 40 ml/min; * pulmonary dysfunction with diffusing capacity for carbon monoxide (dlco) \> 40% and/or need for continuous oxygen supplementation; * karnofsky performance status \> 60%; * patients must give written informed consent; exclusion criteria: * age \> 65 years * previously treated myeloma; * absence of a sibling (genetic randomisation cannot be applied); * karnofsky performance status score \< 60% * hiv-infection; * pregnancy; * refusal to use contraceptive techniques during and for 12 months following treatment * patients unable to give written informed consent ps. informed consent is obtained from each patient according to the institutional review boards of the participating centers. the study is conducted according to the declaration of helsinki.

Keywords: multiple myeloma
long-term treatment with ustekinumab in patients with crohn's disease and ulcerative colitis: a cohort study

Conditions: IBD - Inflammatory Bowel Disease

Summary: monocentric observational retrospective/prospective pharmacological study. clinical records of patients with ulcerative colitis and crohn's disease who started therapy with ustekinumab between february 2019 and march 2021 at the ibd unit will be reviewed. the main objective is to evaluate the overall persistence of patients with crohn's disease and ulcerative colitis who started ustekinumab between february 2019 and march 2021, as well as the impact of treatment on the natural history of the disease. the study involves the collection of follow-up data for a maximum period of 24 months from the start of therapy. for patients who began therapy with ustekinumab from february 2019 up to 24 months before the start of enrollment, data collection will be conducted retrospectively. for patients who have undergone therapy with ustekinumab within 24 months prior to the start of enrollment, and up to march 2021, data will be collected both retrospectively and prospectively.

the medical records of patients with crohn's disease and ulcerative colitis who started therapy with ustekinumab between february 2019 and march 2021 have been selected. initially, it was estimated that approximately 350 patients would be eligible for enrollment in the study.

Eligibility criteria:
inclusion criteria: * signed informed consent * male and female patients, aged ≥18 years * patients who began treatment with ustekinumab according to the indications for marketing authorization, following clinical practice and the information contained in the product's technical data sheet, during the period from february 2019 to march 2021. exclusion criteria: * none